HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Diabetes & Endocrinology
FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
FDA
Apr 9, 2026
Diabetes & Endocrinology
Cohort
Self-management and glycemic control linked to lower MCI risk in rural elderly with type 2 diabetes
Better diabetes self-care linked to lower cognitive decline risk in rural elderly study
A cohort study of 232 rural Chinese elderly with type 2 diabetes found improved self-management behaviors, fewer depressive symptoms, and be…
Better diabetes self-care and mood control in older adults with type 2 diabetes were linked to a lower risk of memory problems in a rural Ch…
Frontiers
Apr 5, 2026
Diabetes & Endocrinology
RCT
Structured exercise program improves glycemic control and fitness in Bangladeshi adults with type 2 diabetes
Can six weeks of guided exercise help manage diabetes better than medication alone?
A 6-week RCT in 90 Bangladeshi adults with type 2 diabetes found that adding a physiotherapist-led exercise program to medication improved c…
Six weeks of guided exercise alongside medication improved blood sugar, walking distance, and quality of life for adults with type 2 diabete…
Apr 3, 2026
Diabetes & Endocrinology
Meta-analysis
SGLT2 inhibitors reduce weight and fat mass in older adults with T2DM, with smaller muscle mass decline
SGLT2 diabetes drugs reduce weight and fat in older adults, with small muscle loss
A meta-analysis of 8 RCTs in 541 older adults with Type 2 diabetes found SGLT2 inhibitors significantly reduced body weight (SMD=-0.85) and …
SGLT2 diabetes drugs help older adults lose weight and fat, but they also cause a small, measurable drop in muscle mass that doctors should …
Apr 2, 2026
Cardiology
Meta-analysis
SGLT2 inhibitors associated with lower mortality in ATTR-CM patients receiving disease-modifying therapy
Could a common diabetes drug help people with a serious heart condition live longer?
A meta-analysis of 7 observational studies including 7,283 patients with ATTR cardiomyopathy found SGLT2 inhibitor use was associated with l…
A common diabetes drug linked to lower death risk and fewer heart attacks for people with a serious heart condition called transthyretin amy…
Apr 2, 2026